Theravance Biopharma Inc

TBPH is exhibiting signs of structural repair with a Bullish Pivot Point pattern and price holding above key short-term EMAs. The intermediate trend is supported by mean-reversion dynamics, while the long-term uptrend remains intact. EMAs are flattening and turning higher, and RSI and Options Score show no exhaustion. The momentum-focused strategy favors participation on shallow pullbacks into rising EMA support.

• ↑$333M cash position and zero debt support trial funding
• ↑UPelry Q1 net sales $71.4M (+15% YoY); hospital doses +49%
• ↓Approval binary risk high: pending Phase III Cypress outcomes